EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
- Author:
Sehhoon PARK
1
;
Bo Mi KU
;
Hyun Ae JUNG
;
Jong-Mu SUN
;
Jin Seok AHN
;
Se-Hoon LEE
;
Keunchil PARK
;
Myung-Ju AHN
Author Information
- Publication Type:Case Report
- From:Cancer Research and Treatment 2020;52(4):1288-1290
- CountryRepublic of Korea
- Language:0
- Abstract: The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.
